Zacks: Brokerages Anticipate Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Will Post Earnings of -$0.45 Per Share

Wall Street brokerages expect Verrica Pharmaceuticals Inc (NASDAQ:VRCA) to post earnings per share of ($0.45) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Verrica Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.47). Verrica Pharmaceuticals reported earnings of ($0.28) per share in the same quarter last year, which would indicate a negative year over year growth rate of 60.7%. The firm is expected to report its next quarterly earnings report on Wednesday, August 5th.

According to Zacks, analysts expect that Verrica Pharmaceuticals will report full year earnings of ($1.94) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($1.73). For the next financial year, analysts anticipate that the company will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.27) to ($1.71). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Verrica Pharmaceuticals.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.01).

VRCA has been the topic of several recent research reports. HC Wainwright cut their price objective on Verrica Pharmaceuticals from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Needham & Company LLC cut their price objective on Verrica Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday. Zacks Investment Research downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, June 25th. ValuEngine upgraded Verrica Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, BidaskClub upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Verrica Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $16.75.

Institutional investors have recently modified their holdings of the company. Citigroup Inc. boosted its position in Verrica Pharmaceuticals by 164.3% during the 4th quarter. Citigroup Inc. now owns 2,585 shares of the company’s stock worth $41,000 after acquiring an additional 1,607 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of Verrica Pharmaceuticals by 54.2% in the first quarter. BNP Paribas Arbitrage SA now owns 4,017 shares of the company’s stock worth $44,000 after purchasing an additional 1,412 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth approximately $69,000. Alliancebernstein L.P. purchased a new position in Verrica Pharmaceuticals during the fourth quarter valued at approximately $160,000. Finally, California Public Employees Retirement System purchased a new position in Verrica Pharmaceuticals during the fourth quarter valued at approximately $185,000. Institutional investors and hedge funds own 34.45% of the company’s stock.

Shares of NASDAQ:VRCA traded up $0.26 on Friday, reaching $10.42. 2,024 shares of the company were exchanged, compared to its average volume of 87,893. The company has a current ratio of 27.45, a quick ratio of 27.45 and a debt-to-equity ratio of 0.61. Verrica Pharmaceuticals has a 1-year low of $6.79 and a 1-year high of $18.67. The firm has a market cap of $284.22 million, a price-to-earnings ratio of -8.61 and a beta of 2.37. The company has a 50-day moving average of $12.11 and a 200-day moving average of $12.74.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Story: How to invest using market indexes

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.